Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology (ASH) 2024 ...

Enitociclib is currently in a Phase 1 dose-escalation study (NTC05371054) evaluating the combination of enitociclib, venetoclax, and prednisone in diffuse large B-cell lymphoma (DLBCL) and peripheral ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Regulation of neutrophil activation plays a ...

in participants with selected CD19+ and CD20+ relapsed/refractory B-cell NHL. The phase 1, open label clinical study is designed to enroll up to 10 participants and is being conducted in ...

ImmPact was developing the technology behind IMPT-314 for B-cell lymphomas as well as for autoimmune conditions, an area of research that’s lately drawn the interest of many cell therapy developers.

in participants with selected CD19+ and CD20+ relapsed/refractory B-cell NHL. The phase 1, open label clinical study is designed to enroll up to 10 participants and is being conducted in Johannesburg, ...

Linker design should balance stability and release kinetics, while payloads should be potent and have minimal toxic side effects. Conjugation methods must ensure uniformity and stability of the ADC.

After four failed rounds of chemotherapy for B cell lymphoma, the professional driver from Bishop's Stortford, Hertfordshire, had about two weeks left to live. She became one of the first patients ...

Department of Nephrology and Immunology, Children’s Hospital of Soochow University, Suzhou, Jiangsu, China In recent years, knowledge regarding immune regulation has expanded rapidly, and major ...

SAVANNAH, Georgia — Inebilizumab, a first-in-class anti-CD19 B-cell depleting agent, demonstrated both safety and superior efficacy compared with placebo in patients with seropositive ...